Stocks · News reference
AstraZeneca Announces The Opening Of Its Newest Global Strategic Research And Development Center, In Kendall Square, Cambridge, Massachusetts; Co. invests $1B To Grow Massachusetts Workforce By Over 50%
$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicinesAstraZeneca today announced the opening of its newest global strategic research and development
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity
Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.